258 related articles for article (PubMed ID: 25966665)
1. Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study.
Jönsson S; Simonsson US; Miller R; Karlsson MO
J Clin Pharmacol; 2015 Nov; 55(11):1268-79. PubMed ID: 25966665
[TBL] [Abstract][Full Text] [Related]
2. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.
Yin OQ; Tetsuya K; Miller R
Eur J Clin Pharmacol; 2014 Nov; 70(11):1339-51. PubMed ID: 25168620
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial.
Krekels EH; Niebecker R; Karlsson MO; Miller R; Shimizu T; Karlsson KE; Ruff CT; Simonsson US; Jönsson S
Clin Pharmacokinet; 2016 Sep; 55(9):1079-90. PubMed ID: 26951208
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Edoxaban in Japanese Atrial Fibrillation Patients With Severe Renal Impairment.
Shimizu T; Tachibana M; Kimura T; Kumakura T; Yoshihara K
Clin Pharmacol Drug Dev; 2017 Sep; 6(5):484-491. PubMed ID: 28032482
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans.
Bathala MS; Masumoto H; Oguma T; He L; Lowrie C; Mendell J
Drug Metab Dispos; 2012 Dec; 40(12):2250-5. PubMed ID: 22936313
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.
Parasrampuria DA; Truitt KE
Clin Pharmacokinet; 2016 Jun; 55(6):641-55. PubMed ID: 26620048
[TBL] [Abstract][Full Text] [Related]
8. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
[TBL] [Abstract][Full Text] [Related]
9. Physiologically-based pharmacokinetic pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contribution.
Xu R; Liu W; Ge W; He H; Jiang Q
CPT Pharmacometrics Syst Pharmacol; 2023 Aug; 12(8):1093-1106. PubMed ID: 37101392
[TBL] [Abstract][Full Text] [Related]
10. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.
Mendell J; Johnson L; Chen S
J Clin Pharmacol; 2015 Dec; 55(12):1395-405. PubMed ID: 26011596
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment.
Song S; Kang D; Halim AB; Miller R
J Clin Pharmacol; 2014 Aug; 54(8):910-6. PubMed ID: 24706516
[TBL] [Abstract][Full Text] [Related]
12. A single and multiple postprandial dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban in healthy Chinese volunteers
.
Chen X; Liu D; Wu Y; Liu Y; Song H; Jiang J; Hu P
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):256-263. PubMed ID: 28025966
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism--the Hokusai-VTE phase 3 study.
Niebecker R; Jönsson S; Karlsson MO; Miller R; Nyberg J; Krekels EH; Simonsson US
Br J Clin Pharmacol; 2015 Dec; 80(6):1374-87. PubMed ID: 26218447
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers.
Yin OQ; Miller R
Clin Drug Investig; 2014 Oct; 34(10):743-52. PubMed ID: 25186833
[TBL] [Abstract][Full Text] [Related]
15. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults.
Mendell J; Chen S; He L; Desai M; Parasramupria DA
Clin Drug Investig; 2015 Jul; 35(7):447-53. PubMed ID: 26068927
[TBL] [Abstract][Full Text] [Related]
16. Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method.
Siriez R; Alpan L; Elasaad K; Devel P; Laloy J; Dogné JM; Douxfils J
J Thromb Thrombolysis; 2020 Apr; 49(3):395-403. PubMed ID: 31925664
[TBL] [Abstract][Full Text] [Related]
17. Edoxaban: a focused review of its clinical pharmacology.
Lip GY; Agnelli G
Eur Heart J; 2014 Jul; 35(28):1844-55. PubMed ID: 24810388
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.
Rohatagi S; Mendell J; Kastrissios H; Green M; Shi M; Patel I; Salazar DE
Thromb Haemost; 2012 Nov; 108(5):887-95. PubMed ID: 23014669
[TBL] [Abstract][Full Text] [Related]
19. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
[TBL] [Abstract][Full Text] [Related]
20. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
Mendell J; Lee F; Chen S; Worland V; Shi M; Samama MM
J Cardiovasc Pharmacol; 2013 Aug; 62(2):212-21. PubMed ID: 23615159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]